NO20072839L - 4-hydroksybenzomorfaner - Google Patents

4-hydroksybenzomorfaner

Info

Publication number
NO20072839L
NO20072839L NO20072839A NO20072839A NO20072839L NO 20072839 L NO20072839 L NO 20072839L NO 20072839 A NO20072839 A NO 20072839A NO 20072839 A NO20072839 A NO 20072839A NO 20072839 L NO20072839 L NO 20072839L
Authority
NO
Norway
Prior art keywords
hydroksybenzomorfaner
hydroxybenzomorphans
thiocarboxamide
antitussives
anticonvulsants
Prior art date
Application number
NO20072839A
Other languages
English (en)
Other versions
NO340204B1 (no
Inventor
Mark P Wentland
Original Assignee
Rensselaer Polytech Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rensselaer Polytech Inst filed Critical Rensselaer Polytech Inst
Publication of NO20072839L publication Critical patent/NO20072839L/no
Publication of NO340204B1 publication Critical patent/NO340204B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/26—Benzomorphans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

4-Hydroksybenzomorfaner som inneholder karboksamid eller tiokarboksamid i 3-posisjon er nyttige som analgetiske midler, anti-diaré midler, antikonvulsanter, antitussiver og anti-avhengighet medisinering.
NO20072839A 2004-11-05 2007-06-04 4-hydroksybenzomorfaner NO340204B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62534804P 2004-11-05 2004-11-05
PCT/US2005/039911 WO2006052710A1 (en) 2004-11-05 2005-11-03 4-hydroxybenzomorphans

Publications (2)

Publication Number Publication Date
NO20072839L true NO20072839L (no) 2007-08-03
NO340204B1 NO340204B1 (no) 2017-03-20

Family

ID=36128632

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072839A NO340204B1 (no) 2004-11-05 2007-06-04 4-hydroksybenzomorfaner

Country Status (20)

Country Link
US (7) US7262298B2 (no)
EP (2) EP2251330B1 (no)
JP (3) JP5198067B2 (no)
KR (1) KR101115841B1 (no)
CN (1) CN101090891B (no)
AT (1) ATE557006T1 (no)
AU (1) AU2005304950B2 (no)
BR (1) BRPI0517091B8 (no)
CA (1) CA2587074C (no)
CY (1) CY1112946T1 (no)
DK (1) DK2251330T3 (no)
ES (1) ES2387737T3 (no)
IL (1) IL182983A (no)
MX (1) MX2007005389A (no)
NO (1) NO340204B1 (no)
PL (1) PL2251330T3 (no)
PT (1) PT2251330E (no)
RU (2) RU2480455C2 (no)
SI (1) SI2251330T1 (no)
WO (1) WO2006052710A1 (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE292625T1 (de) * 2000-10-31 2005-04-15 Rensselaer Polytech Inst 8-substituierte 2,6-methano-3-benzazocine und 3- substituierte morphinane als opioidrezeptorbindende agenzien
RU2480455C2 (ru) * 2004-11-05 2013-04-27 Ренссилэйер Политекник Инститьют 4-гидроксибензоморфаны
WO2007014137A2 (en) 2005-07-21 2007-02-01 Rensselaer Polytechnic Institute 8-carboxamido-substituted-2 , 6-methano-3-benzazocines and 3 - carboxamido- substituted morphanes as opioid receptor binding agents
ATE493416T1 (de) 2007-05-04 2011-01-15 Mallinckrodt Inc Verbessertes verfahren zur herstellung von 6- alpha-hydroxy-n-alkylierten opiaten
AU2008276385B2 (en) 2007-07-17 2013-07-18 SpecGx LLC Preparation of N-alkylated opiates by reductive amination
US8263807B2 (en) 2007-08-09 2012-09-11 Rensselaer Polytechnic Institute Quaternary opioid carboxamides
NZ607842A (en) 2008-09-30 2013-12-20 Mallinckrodt Llc Processes for the selective amination of ketomorphinans
US8946419B2 (en) 2009-02-23 2015-02-03 Mallinckrodt Llc (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
EP2408303A4 (en) * 2009-03-19 2012-07-25 Alkermes Inc MORPHINANE DERIVATIVES HAVING HIGH ORAL BIOLOGICAL AVAILABILITY
WO2010118274A1 (en) * 2009-04-09 2010-10-14 Mallinckrodt Inc. Preparation of 6-keto, 3-alkoxy morphinans
EP2440562B1 (en) 2009-06-11 2016-08-10 Mallinckrodt LLC Preparation of 6-alpha-amino n-substituted morphinans by catalytic hydrogen transfer
ES2465066T3 (es) 2009-06-11 2014-06-05 Mallinckrodt Llc Aminación reductora de 6-ceto-normorfinanos por transferencia de hidrógeno catalítica
PT2506712T (pt) * 2009-12-04 2019-05-31 Alkermes Pharma Ireland Ltd Derivados de morfinano para o tratamento da overdose por fármaco
ES2582306T3 (es) * 2010-03-22 2016-09-12 Rensselaer Polytechnic Institute Derivados de morfinano que contienen un grupo carboxamida como ligandos de receptores opioides
ES2527315T3 (es) 2010-04-29 2015-01-22 Mallinckrodt Llc Preparación de compuestos morfinano con cetona saturada que tienen un bajo contenido en metal
JP5728084B2 (ja) 2010-07-08 2015-06-03 アルカーメス ファーマ アイルランド リミテッド 置換モルフィナンの合成のための方法
HRP20240109T1 (hr) 2010-08-23 2024-03-29 Alkermes Pharma Ireland Limited Postupci za liječenje povećanja tjelesne težine induciranog antipsihoticima
US9029543B2 (en) 2011-04-05 2015-05-12 Alkermes, Inc. Process for the synthesis of quaternary amine compounds
CN103717601A (zh) 2011-06-09 2014-04-09 马林克罗特有限公司 通过催化氢转移对6-酮基吗啡喃的还原胺化
ES2638329T3 (es) 2011-06-29 2017-10-19 Alkermes, Inc. Compuestos opioides de acción periférica
BR112014005421A2 (pt) 2011-09-08 2017-04-04 Mallinckrodt Llc produção de alcaloides sem o isolamento de intermediários
EP3153171B1 (en) 2011-12-15 2018-09-19 Alkermes Pharma Ireland Limited Samidorphan (alks 33) in combination with buprenorphine for the treatment of depressive disorders
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
ES2770978T3 (es) 2013-05-24 2020-07-06 Alkermes Pharma Ireland Ltd Análogos de morfanos y morfinanos y métodos de uso
WO2014190271A2 (en) 2013-05-24 2014-11-27 Alkermes Pharma Ireland Limted Methods for treating depressive symptoms
CA3054122A1 (en) * 2017-03-02 2018-09-07 Ube Industries, Ltd. Therapeutic agent for alcohol use disorders
CN107089948B (zh) * 2017-04-28 2020-07-17 云南大学 吗吩衍生物及其制备方法和应用
CN111978252A (zh) * 2019-05-21 2020-11-24 复旦大学 手性苯并吗吩烷类衍生物及其制备方法和在药学上的应用
TW202140009A (zh) * 2020-02-13 2021-11-01 大陸商上海翰森生物醫藥科技有限公司 ３－甲醯胺基－４－羥基納曲酮氘代衍生物、其製備方法及其在醫藥上的應用
CN111205151B (zh) * 2020-02-29 2021-03-05 深圳市祥根生物科技有限公司 一种布洛芬杂质i的环保制备方法
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet
CN114621238B (zh) * 2020-12-10 2026-02-03 鲁南制药集团股份有限公司 一种制备纳呋拉啡的方法
KR102663533B1 (ko) * 2021-11-09 2024-05-08 백미선 레이저 치료기기용 온냉각장치

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032529A (en) 1974-09-20 1977-06-28 Sterling Drug Inc. Aminomethanobenzazocine intermediates
US3957793A (en) 1974-09-20 1976-05-18 Sterling Drug Inc. Hydroxyiminobenzazocines
SU635868A3 (ru) * 1974-11-12 1978-11-30 Бристол Мейерз Компани (Фирма) Способ получени морфиновых производных или их солей
US4205171A (en) 1976-01-12 1980-05-27 Sterling Drug Inc. Aminomethanobenzazocines and nitromethanobenzazocines
US4373139A (en) 1979-04-30 1983-02-08 Motorola, Inc. Detectors
US4649200A (en) 1986-05-08 1987-03-10 Regents Of The University Of Minnesota Substituted pyrroles with opioid receptor activity
EP0632041A1 (en) 1993-07-01 1995-01-04 Katholieke Universiteit Nijmegen New morphine derivatives having improved analgesic and narcotic properties
KR19990077125A (ko) 1996-01-10 1999-10-25 파올로 비지, 엔리꼬 카쭐라니 헤테로고리-축합 모르핀 유도체 (ⅱ)
ATE292625T1 (de) 2000-10-31 2005-04-15 Rensselaer Polytech Inst 8-substituierte 2,6-methano-3-benzazocine und 3- substituierte morphinane als opioidrezeptorbindende agenzien
AU2003281060A1 (en) 2002-07-16 2004-02-02 Rensselaer Polytechnic Institute Process for conversion of phenols to carboxamides via the succinimide esters
RU2480455C2 (ru) * 2004-11-05 2013-04-27 Ренссилэйер Политекник Инститьют 4-гидроксибензоморфаны

Also Published As

Publication number Publication date
CN101090891A (zh) 2007-12-19
SI2251330T1 (sl) 2012-09-28
US20060111384A1 (en) 2006-05-25
CN101090891B (zh) 2012-08-01
US20240092740A1 (en) 2024-03-21
BRPI0517091A (pt) 2008-09-30
EP2251330B1 (en) 2012-05-09
JP6058981B2 (ja) 2017-01-11
JP2016020364A (ja) 2016-02-04
US20140148475A1 (en) 2014-05-29
US20150011768A1 (en) 2015-01-08
US8802655B2 (en) 2014-08-12
CY1112946T1 (el) 2016-04-13
US7262298B2 (en) 2007-08-28
US8680112B2 (en) 2014-03-25
DK2251330T3 (da) 2012-08-06
KR20070085723A (ko) 2007-08-27
IL182983A (en) 2012-06-28
JP2013067636A (ja) 2013-04-18
EP1817291A1 (en) 2007-08-15
US20130231361A1 (en) 2013-09-05
MX2007005389A (es) 2007-12-07
AU2005304950A1 (en) 2006-05-18
RU2007120759A (ru) 2008-12-10
US20070238748A1 (en) 2007-10-11
WO2006052710A1 (en) 2006-05-18
US20160075658A1 (en) 2016-03-17
EP2251330A1 (en) 2010-11-17
ATE557006T1 (de) 2012-05-15
PL2251330T3 (pl) 2012-12-31
BRPI0517091B8 (pt) 2021-05-25
JP2008519035A (ja) 2008-06-05
RU2480455C2 (ru) 2013-04-27
JP5198067B2 (ja) 2013-05-15
RU2415131C2 (ru) 2011-03-27
AU2005304950B2 (en) 2010-12-09
KR101115841B1 (ko) 2012-03-09
CA2587074A1 (en) 2006-05-18
IL182983A0 (en) 2007-08-19
RU2010147915A (ru) 2012-05-27
ES2387737T3 (es) 2012-10-01
CA2587074C (en) 2012-09-04
PT2251330E (pt) 2012-07-20
BRPI0517091B1 (pt) 2019-10-08
NO340204B1 (no) 2017-03-20

Similar Documents

Publication Publication Date Title
NO20072839L (no) 4-hydroksybenzomorfaner
HRP20070374T3 (en) Formulations comprising ecteinascidin and a disaccharide
NO20052739D0 (no) CCR5-antagonister som medikamenter
NO20014963D0 (no) Cycloalkyl-substituerte benzimidazoler, samt fremstilling og anvendelse derav
UA85574C2 (uk) Ендопаразитоцидний засіб для місцевого застосування
WO2004028475A3 (en) Glycosylceramide analogues
NO20052534D0 (no) Oksazolidinon- og/eller isokazolinderivater som antibakterielle stoffer
DK1667668T3 (da) Alfabeta3 og altabeta6-integrinantagonister som antifibrotiske midler
WO2007014137A3 (en) 8-carboxamido-substituted-2 , 6-methano-3-benzazocines and 3 - carboxamido- substituted morphanes as opioid receptor binding agents
MY139425A (en) Pharmaceutical composition comprising 2,4-dichlorobenzyl alcohol and amylmetacresol
MX2007007355A (es) 5-(2,2-dimetil-ciclopropil)-3-metil-pen-2-en nitrilo como fragancia y sabor.
DE60319388D1 (de) C6- UND C9-SUBSTITUIERTE CHROMENOÄ4,3-cÜISOXAZOLIN
FR2835436B1 (fr) Instrumentation pour analgesie, notamment peridurale
EP1556022A4 (en) Aqueous 2,6-diisopropylprophenol-containing pharmaceutical compositions
ITMI20022781A1 (it) Composizione per prodotti dermatologici ad azione topica e prodotti dermatologici realizzati con questa composizione.
ITBO20040403A1 (it) Riduttore di velocita', particolarmente per estrusori, e simili
ITGE20030111A1 (it) Anta, in particolare per armadi e simili.
ITMI20022352A1 (it) Preparazioni antitumorali contenenti resveratrolo e propoli.
ITMO990010V0 (it) Anta sagomata per mobili e simili.
FR2836043B1 (fr) Vesicules lipidiques, preparation et utilisations
ES1051272Y (es) Peonza multiplicable.
ITMI20030317A1 (it) Terapia combinata comprendente un derivato dell'indolopirrolocarbazolo ed un altro agente antitumorale.
ES1053325Y (es) Pastilla-mascara para tratamientos faciales.
ES1051120Y (es) Mecanismo modificador del efecto sonoro en sordinas.
ES1051932Y (es) Estructura para ventanas y similares.